NovaBridge Biosciences
NBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001778016
In the last 90 days, NovaBridge Biosciences insiders filed 0 open-market purchases and 3 sales; 49 institutions reported holding it in 13F filings for Q2 2026, worth $48.1M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q4 2024 vs. Q3 2024
How the institutions holding NovaBridge Biosciences changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 28 | 28 | 0 |
| Shares | 14.2M | 11.9M | −2.28M (−16.1%) |
| Value | $17.6M | $10.1M | −$7.48M (−42.5%) |
New holders (7)
Institutions that held NovaBridge Biosciences at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| SG Americas Securities, LLC | 475,862 | $404.0K | 0.00% |
| Cantor Fitzgerald, L. P. | 140,100 | $119.1K | 0.00% |
| BNP Paribas Arbitrage, SA | 109,209 | $92.8K | 0.00% |
| UBS Group AG | 103,054 | $87.6K | 0.00% |
| HRT Financial LP | 13,087 | $11.0K | 0.00% |
| SBI Securities Co., Ltd. | 905 | $769 | 0.00% |
| Vermillion Wealth Management, Inc. | 200 | $170 | 0.00% |
Sold out (7)
Institutions that held NovaBridge Biosciences at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Caligan Partners LP | 3,499,330 | $4.34M |
| Boothbay Fund Management, LLC | 1,419,080 | $1.76M |
| Temasek Holdings (Private) Ltd | 566,650 | $702.6K |
| XTX Topco Ltd | 43,039 | $53.4K |
| Susquehanna International Group, LLP | 13,351 | $16.6K |
| Tower Research Capital LLC (TRC) | 4,015 | $4.98K |
| BlackRock, Inc. | 1,438 | $1.78K |